Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128835) titled 'Study on the Neoadjuvant Therapy of NSCLC with Chronic Pain Using Remeglitazone Combined with Immunochemotherapy' on July 27.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Harbin Medical University Cancer Hospital

Condition: Resectable stage IB-IIIB non-small cell lung cancer (NSCLC) with chronic pain

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-08-19

Target Sample Size: experimental group:12;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=334568

Disclaimer: Curated by HT Syndication....